Logo image
The Low Prevalence and High Cost of Routine Antiphospholipid Antibody Testing in Patients with Recurrent Pregnancy Loss
Journal article   Open access   Peer reviewed

The Low Prevalence and High Cost of Routine Antiphospholipid Antibody Testing in Patients with Recurrent Pregnancy Loss

Renee G Cafun, Anna Merrill, Sharathkumar M Bhagavathi, Karen M Summers, Brittany A Bettendorf and Bradley J Van Voorhis
Fertility and sterility, Vol.119(6), pp.1078-1080
06/2023
DOI: 10.1016/j.fertnstert.2023.03.026
PMID: 36972747
url
https://doi.org/10.1016/j.fertnstert.2023.03.026View
Published (Version of record) Open Access

Abstract

Objective Testing for antiphospholipid antibodies (aPLs) is recommended and widely practiced for patients with recurrent pregnancy loss (RPL) based, in part, on a reported prevalence of antiphospholipid syndrome ranging from 8%–42% in patients experiencing multiple miscarriages (1). However, this prevalence may be inflated because these studies were performed before the implementation of new standardized guidelines for aPLs testing. Our primary objective was to evaluate the rate of confirmed aPL positivity in patients with RPL as currently defined by the American Society for Reproductive Medicine practice guidelines and according to the international recommendations for proper laboratory testing. Secondary objectives were to determine the costs associated with aPL testing and the clinical factors associated with aPL positivity among patients with RPL. The University of Iowa Institutional Review Board reviewed and approved the methods for this study (IRB# 202112378).

Details

Metrics

Logo image